Effects of rifampin, a potent inducer of drug-metabolizing enzymes and an inhibitor of oatp1b1/3 transport, on the single dose pharmacokinetics of anacetrapib

Journal of Clinical Pharmacology

Volumn 53, Issue 7, 2013, Pages 746-752

  Anderson, Matt S ^a   Cote, Josee ^a   Liu, Yang ^a   Stypinski, Daria ^b   Auger, Patrice ^b   Hohnstein, Anne ^b   Rasmussen, Scott ^b   Johnson Levonas, Amy O ^a   Gutstein, David E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CELERION   (United States)

Author keywords

Anacetrapib; CYP3A isozymes inducer; Drug drug interaction; OATP1B1 3 inhibitor; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ANACETRAPIB; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 3A; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; OXAZOLIDINONES; RIFAMPIN; YOUNG ADULT;

EID: 84880259497     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.97     Document Type: Article

References (7)

1. Krishna R, Bergman AJ, Jin B, et al. Assessment of the CYP3Amediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharmacol. 2009;49:80-87.
2. Krishna R, Stypinski D, Ali M, et al. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects. Biopharm Drug Dispos. 2011;32:525-529.
3. Choi MK, Jin QR, Choi YL, Ahn SH, Bae MA, Song IS. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. Biopharm Drug Dispos. 2011;32:175-184.
4. Reitman ML, Chu X, Cai X, et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89:234-242.
5. Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther. 2008;84:679-683.
6. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy,safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy, coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352-360.
7. Krishna R, Bergman AJ, Green M, Dockendorf MF, Wagner JA, Dykstra K. Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor. AAPS J. 2011;13: 179-190.